Global Respiratory Disease Testing Market 2024-2031

Description

List of Tables

Global Respiratory Disease Testing Market Size, Share & Trends Analysis Report by Product and Service (Instruments & Devices, Assays & Reagents, and Services & Software), by Test Type (Imaging Tests, Mechanical Tests, and In-vitro Diagnostic Tests), by Disease Indication (Tuberculosis, Asthma, Lung Cancer, Chronic Obstructive Pulmonary Disease, and Others) and by End Users (Hospitals and Clinics, Diagnostics Laboratories, and Others) Forecast Period (2024-2031)

The global respiratory disease testing market is anticipated to grow at a considerable CAGR of 6.3% during the forecast period (2024-2031). The primary driver propelling the market's expansion is the progressively increasing prevalence of respiratory diseases caused by rising air pollution levels. The growth has been prompted by the increasing rate of air pollution and the release of dangerous chemicals leading to lung ailments, such as chronic obstructive pulmonary disease (COPD), and other respiratory diseases globally. The development of diseases such as tuberculosis and hospital-acquired infections, since these tests are utilized as early detection tools, are additional drivers propelling the overall growth.

Market Dynamics

Increasing Prevalence of Aging Population

The increasing prevalence of COPD is attributed to the aging population, leading to it being necessary to employ tactics such as integrated care models and individualized treatment plans to effectively manage the aforementioned age trend. According to the National Centre for Biotechnology Information, in December 2023, it is projected that the global number of COPD cases among individuals aged 25 years and older will experience a 23.0% increase from 2020 to 2050, resulting in an estimated 600.0 million patients globally by 2050. The burden of COPD is expected to grow significantly in low- and middle-income regions, with the number of cases in women projected to increase by 47.1% compared to a 9.4% increase for men. Additionally, the number of cases in low- and middle-income regions is anticipated to surpass that of high-income regions by 2050.

Technological Advancements

Technological advancements in data analytics and visualization are driving the development of interactive dashboards and detailed reports for respiratory virus monitoring tools. For instance, in January 2024, the Texas Department of State Health Services introduced new data tools to monitor respiratory viruses in the state. The dashboard displays trends in illnesses from influenza, COVID-19, and RSV, including emergency room visits, hospitalizations, and deaths. The weekly report provides in-depth information on these diseases.

Market Segmentation

Our in-depth analysis of the global respiratory disease testing market includes the following segments by product and service, application, disease indication, and end-user:

Based on product and service, the market is sub-segmented into instruments & devices, assays & reagents, and services & software.
based on application, the market is sub-segmented into imaging tests, mechanical tests, and in-vitro diagnostic tests.
Based on disease indication, the market is bifurcated into tuberculosis, asthma, lung cancer, chronic obstructive pulmonary disease, and others (interstitial lung disease (ILD), and sleep apnea).
Based on end-users, the market is sub-segmented into hospitals and clinics, diagnostics laboratories, and others (ambulatory care centers, and government health agencies).

Tuberculosis is Projected to Emerge as the Largest Segment

Based on the disease indication, the global respiratory disease testing market is sub-segmented into tuberculosis, asthma, lung cancer, chronic obstructive pulmonary disease, and others. Among these, the tuberculosis sub-segment is expected to hold the largest share of the market. The primary factor supporting the segment's growth includes investments in research and development for respiratory illness testing technologies are increasing diagnostic accessibility, efficacy, and accuracy, which enhances global initiatives to control tuberculosis. According to the World Health Organization in 2023, 1.3 million individuals died from TB, making it the second leading infectious killer after COVID-19. TB affects 10.6 million individuals globally, with multidrug-resistant TB remaining a public health crisis. Despite efforts to save 75.0 million lives since 2000, $13.0 billion is needed annually for prevention, diagnosis, treatment, and care to achieve the UN Sustainable Development Goals of ending TB by 2030.

In-vitro Diagnostic Tests Sub-segment to Hold a Considerable Market Share

The increasing need for accurate diagnosis of respiratory diseases is met by multiplex testing, which renders it accessible to diagnose patients rapidly and treat patients, especially during viral periods of high activity. For instance, in July 2022, Hologic launched Panther Fusion SARS-CoV-2/Flu A/B/RSV assay and Novodiag RESP-4 molecular diagnostic test for sale in the European Union. These tests detect and differentiate four prevalent respiratory viruses namely SARS-CoV-2, influenza A, influenza B, and RSV. Both tests are compliant with the European In Vitro Diagnostic Medical Device Directive (IVDD) 98/79/EC and EU 2017/746.

Regional Outlook

The global respiratory disease testing market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Healthcare access and infrastructure In Asia-Pacific Region

The demand for respiratory disease testing is influenced by healthcare access and infrastructure, with countries with robust systems and adequate facilities experiencing higher testing rates. According to the Union Budget, in February 2023, allocated $11.322 billion for the Ministry of Health, 3.4% higher than FY23's $10.9 billion, with $10.9 billion for health and family welfare and $3.8 for Health Research.

North America Holds Major Market Share

The high incidence of lung cancer in the US has led to an increased need for respiratory disease testing, specifically for the early identification and management of the condition. This demand places a significant strain on healthcare systems and individuals influenced by the disease, highlighting the importance of effective screening and treatment measures. According to the Lung Cancer Research Foundation, in 2023, lung cancer accounts for the highest number of cancer-related deaths globally, with an estimated 238,340 new cases expected to be diagnosed in the US in 2023. The lifetime risk of developing lung cancer is 1 in 16, affecting both men and women, and approximately 127,070 lives are lost to the disease each year in America.

The major companies serving the global respiratory disease testing market include Abbott Laboratories, Becton, Dickinson, and Co., Koninklijke Philips N.V., Merck KGaA, and Siemens Healthineers AG, among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers, and acquisitions to stay competitive in the market. for instance, in February 2024, GSK acquired Aiolos Bio, a biopharmaceutical company focusing on treating respiratory and inflammatory conditions. The acquisition includes AIO-001, a long-acting anti-thymic stromal lymphopoietin monoclonal antibody for adult asthma treatment. This could expand GSK's respiratory biologics portfolio to 40.0% of severe asthma patients with low T2 inflammation.

In December 2023, AstraZeneca acquired Icosavax, the acquisition strengthened AstraZeneca's vaccines & immune therapies late-stage pipeline, including IVX-A12, a potential first-in-class, Phase III-ready, combination protein VLP vaccine targeting both RSV and human metapneumovirus. IVX-A12 has a differentiated profile compared to currently approved RSV vaccines.

Product Code: OMR2028546

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Industry Trends
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
3.2. Abbott Laboratories
- 3.2.1. Overview
- 3.2.2. Financial Analysis
- 3.2.3. SWOT Analysis
- 3.2.4. Recent Developments
3.3. Becton, Dickinson, and Co.
- 3.3.1. Overview
- 3.3.2. Financial Analysis
- 3.3.3. SWOT Analysis
- 3.3.4. Recent Developments
3.4. Koninklijke Philips N.V.
- 3.4.1. Overview
- 3.4.2. Financial Analysis
- 3.4.3. SWOT Analysis
- 3.4.4. Recent Developments
3.5. Key Strategy Analysis

4. Market Segmentation

4.1. Global Respiratory Disease Testing Market by Product and Service
- 4.1.1. Instruments & Devices
- 4.1.2. Assays & Reagents
- 4.1.3. Services & Software
4.2. Global Respiratory Disease Testing Market by Test Type
- 4.2.1. Imaging Tests
- 4.2.2. Mechanical Tests
- 4.2.3. In-vitro Diagnostic Tests
4.3. Global Respiratory Disease Testing Market by Disease Indication
- 4.3.1. Tuberculosis
- 4.3.2. Asthma
- 4.3.3. Lung Cancer
- 4.3.4. Chronic Obstructive Pulmonary Disease
- 4.3.5. Others (Interstitial Lung Disease (ILD), and Sleep Apnea)
4.4. Global Respiratory Disease Testing Market by End-user
- 4.4.1. Hospitals and Clinics
- 4.4.2. Diagnostics Laboratories
- 4.4.3. Others (Ambulatory Care Centers, and Government Health Agencies)

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
- 5.4.1. Latin America
- 5.4.2. Middle East & Africa

6. Company Profiles

6.1. Bedfont Scientific Ltd.
6.2. BIOMERIEUX
6.3. Carestream Health, Inc.
6.4. Danaher Corp.
6.5. F. Hoffmann-La Roche Ltd
6.6. Masimo Corp.
6.7. Medtronic Plc
6.8. Merck KGaA
6.9. MGC Diagnostics Corp.
6.10. Nihon Kohden Corp.
6.11. QIAGEN GmbH
6.12. ResMed Corp.
6.13. Siemens Healthineers AG
6.14. Smiths Group plc
6.15. Sysmex Corp.
6.16. Thermo Fisher Scientific Inc.
6.17. Vitalograph